Karen Akinsanya - 02 Mar 2026 Form 4 Insider Report for Schrodinger, Inc. (SDGR)

Reporting relationship: President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships
Issuer ticker: SDGR
Reported as of: 02 Mar 2026
Net transaction value: -$26,454
SEC form: 4
Accepted by SEC: 03 Mar 2026, 16:31:41 UTC
Prior SEC filing: 25 Jun 2025
Next SEC filing: 06 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Donald Shum, as attorney-in-fact for Karen Akinsanya

Key filing fact

Karen Akinsanya filed Form 4 for Schrodinger, Inc. (SDGR) on 03 Mar 2026.

Key facts

This page summarizes Karen Akinsanya's Form 4 filing for Schrodinger, Inc. (SDGR).
5 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Mar 2026, 16:31.

Change

Previous filing in this sequence was filed on 25 Jun 2025.
Current net transaction value: -$26,454.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001797672 Primary reporting owner

Akinsanya Karen

Relationship: President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships
Address: C/O SCHRODINGER, INC.,, 1540 BROADWAY, 24TH FLOOR, NEW YORK
Signature: /s/ Donald Shum, as attorney-in-fact for Karen Akinsanya
Signature date: 03 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SDGR transaction

Common Stock

Award

Transaction value: $0
Shares: +24,250
Change %: +155%
Price: $0.000000
Shares after: 39,875
Date: 02 Mar 2026
Ownership: Direct
Footnotes: F1

SDGR transaction

Common Stock

Award

Transaction value: $0
Shares: +6,077
Change %: +15%
Price: $0.000000
Shares after: 45,952
Date: 02 Mar 2026
Ownership: Direct
Footnotes: F2

SDGR transaction

Common Stock

Award

Transaction value: $0
Shares: +27,576
Change %: +60%
Price: $0.000000
Shares after: 73,528
Date: 02 Mar 2026
Ownership: Direct
Footnotes: F3

SDGR transaction

Common Stock

Sale

Transaction value: $26,454
Shares: -2,206
Change %: -3%
Price: $11.99
Shares after: 71,322
Date: 02 Mar 2026
Ownership: Direct
Footnotes: F4, F5, F6

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SDGR transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +48,500
Change %
Price: $0.000000
Shares after: 48,500
Date: 02 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 48,500
Exercise price: $12.15
Footnotes: F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 7 footnotes

Footnote F1

Grant of restricted stock units ("RSUs") under the Issuer's 2022 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs were granted on March 2, 2026 and will vest in equal installments on each of March 9, 2027, 2028, 2029 and 2030, subject to the reporting person's continued service with the company.

Footnote F2

Represents the portion of the performance-based restricted stock units ("PRSUs") that were previously granted to the reporting person on February 9, 2023 in connection with the Issuer's annual grant of equity in 2023, that vested on March 2, 2026 following certification by the compensation committee of the Issuer's board of directors of the level of achievement of certain performance metrics for the PRSUs.

Footnote F3

Represents PRSUs previously granted to the reporting person on March 4, 2024, for which the compensation committee of the Issuer's board of directors certified on March 2, 2026 the level of achievement of the performance metrics for the PRSUs. The PRSUs will vest upon the filing of the Issuer's Annual Report on Form 10-K for the year ended December 31, 2026, subject to the reporting person's continued service with the company.

Footnote F4

This sale was effected pursuant to a durable automatic sale instruction under Rule 10b5-1 adopted by the reporting person on March 8, 2023, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PRSUs. The sale does not represent a discretionary trade by the reporting person.

Footnote F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.70 to $12.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) of this Form 4.

Footnote F6

Includes an aggregate of 67,451 unvested RSUs.

Footnote F7

The option was granted on March 2, 2026. The shares underlying the option are scheduled to vest with respect to 25% of the shares on March 2, 2027 and the remainder are scheduled to vest in equal monthly installments through March 2, 2030, subject to the reporting person's continued service with the company.

SEC remarks

President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships